tirzepatide name Zepbound vs Tirzepatide: Differences, Cost & Weight Loss Results Yesterday the FDA approved tirzepatide

GLP-1 weight loss coverage is expanding fast

Response timing varies based on dosage, metabolism, and genetic factors in GLP-1 receptor pathways

Abstract: | 52 comments on LinkedIn

Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD 8.92 (11.59 to 6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and drug overdose (0.61 (0.42 to 0.88), NRD 1.49 (2.43 to 0.55)) and suicidal ideation or attempt (0.75 (0.67 to 0.83), NRD 9.95 (13.14 to 6.77))

To mark 50 years of monoclonal antibodies, this Review from Chan, Martyn and Carter provides an overview of how antibody engineering strategies have continued to improve antibody-based therapeutics, chiefly focusing on antibody-mediated targeting of B cells and also human epidermal growth factor receptor 2 (HER2)+ cancers

Chronic Overweight & Anti-Obesity Management: Serves as an efficient long-term framework to drive deep adipose tissue reduction and sustain lean body composition